AU2018378981B2 - Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye - Google Patents

Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye Download PDF

Info

Publication number
AU2018378981B2
AU2018378981B2 AU2018378981A AU2018378981A AU2018378981B2 AU 2018378981 B2 AU2018378981 B2 AU 2018378981B2 AU 2018378981 A AU2018378981 A AU 2018378981A AU 2018378981 A AU2018378981 A AU 2018378981A AU 2018378981 B2 AU2018378981 B2 AU 2018378981B2
Authority
AU
Australia
Prior art keywords
eye
acid
day
pharmaceutically acceptable
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018378981A
Other languages
English (en)
Other versions
AU2018378981A1 (en
Inventor
Xavier CAPDEVILA NORTES
Maria Isabel DELGADO GAÑÁN
Javier SANAGUSTÍN AQUILUÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Publication of AU2018378981A1 publication Critical patent/AU2018378981A1/en
Application granted granted Critical
Publication of AU2018378981B2 publication Critical patent/AU2018378981B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018378981A 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye Active AU2018378981B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382832 2017-12-04
EP17382832.8 2017-12-04
PCT/EP2018/082999 WO2019110416A1 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Publications (2)

Publication Number Publication Date
AU2018378981A1 AU2018378981A1 (en) 2020-07-16
AU2018378981B2 true AU2018378981B2 (en) 2024-10-24

Family

ID=60673756

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018378981A Active AU2018378981B2 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Country Status (24)

Country Link
US (1) US20200390729A1 (enExample)
EP (1) EP3720428B1 (enExample)
JP (1) JP2021505554A (enExample)
KR (1) KR102756155B1 (enExample)
CN (1) CN111542316A (enExample)
AU (1) AU2018378981B2 (enExample)
BR (1) BR112020011160A2 (enExample)
CA (1) CA3083835A1 (enExample)
CL (1) CL2020001426A1 (enExample)
DK (1) DK3720428T3 (enExample)
ES (1) ES2941036T3 (enExample)
FI (1) FI3720428T3 (enExample)
HR (1) HRP20230319T1 (enExample)
HU (1) HUE061852T2 (enExample)
MA (1) MA50991B1 (enExample)
MX (1) MX2020005809A (enExample)
MY (1) MY205498A (enExample)
PH (1) PH12020550722A1 (enExample)
PL (1) PL3720428T3 (enExample)
PT (1) PT3720428T (enExample)
SG (1) SG11202004940VA (enExample)
SI (1) SI3720428T1 (enExample)
WO (1) WO2019110416A1 (enExample)
ZA (1) ZA202003944B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300017430A1 (it) * 2023-08-22 2025-02-22 Service Biotech srl Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio
CN117257963B (zh) * 2023-11-02 2024-07-16 广州准优生物科技有限公司 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途
CN117643573B (zh) * 2024-01-29 2024-05-03 天津医科大学眼科医院 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777699A1 (en) * 2012-02-02 2014-09-17 Luis Antonio Outeirino Miguez Use of 2,5-dihydroxbencene sulfonic acid (dobesilate) for the treatment of age-related macular degeneration
EP2875811A1 (en) * 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
BR112014013041A2 (pt) * 2011-11-30 2019-09-24 Xigen Inflammation Ltd uso de inibidores de peptídeos de permeação celular do curso de transdução de sinal de jnk para o tratamento da síndrome do olho seco
EA201491643A1 (ru) * 2012-03-05 2015-02-27 Уэйн Стейт Юниверсити Идентификация мутаций канал-опсина-2 (chop2) и способы применения
CA2871528A1 (en) * 2012-04-24 2013-10-31 Thrombogenics N.V. Anti-pdgf-c antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777699A1 (en) * 2012-02-02 2014-09-17 Luis Antonio Outeirino Miguez Use of 2,5-dihydroxbencene sulfonic acid (dobesilate) for the treatment of age-related macular degeneration
EP2875811A1 (en) * 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J NIRMAL ET AL: "Evaluation of stability and in vivo trans-corneal penetration of 1% topical calcium dobesilate formulation", INDIAN JOURNAL OF PHARMACOLOGY 41ST ANNUAL CONFERENCE OF INDIAN-PHARMACOLOGICAL-SOCIETY, 1 October 2008 *
P. CUEVAS ET AL: "Topical dobesilate eye drops for ophthalmic primary pterygium", BMJ CASE REPORTS, vol. 2012, no. mar08 1, 8 March 2012 (2012-03-08), UK, XP055474235, ISSN: 1757-790X, DOI: 10.1136/bcr.12.2011.5449 *
PEDRO CUEVAS ET AL: "Improvement in the signs and symptoms of dry eye disease with dobesilate eye drops", MILITARY MEDICAL RESEARCH, vol. 2, no. 1, 1 December 2015 (2015-12-01), XP055474245, DOI: 10.1186/s40779-015-0068-8 *
RAFAEL SIMÓ: "Mechanisms of retinal neuroprotection of calcium dobesilate: therapeutic implications", NEURAL REGENERATION RESEARCH, vol. 12, no. 10, 1 October 2017 (2017-10-01), pages 1620 - 1622, XP055474254 *
VELPANDIAN T ET AL: "EVALUATION OF CALCIUM DOBESILATE FOR ITS ANTI-CATARACT POTENTIAL IN EXPERIMENTAL ANIMAL MODELS", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 32, no. 3, 31 March 2010, pages 171 - 179 *

Also Published As

Publication number Publication date
WO2019110416A1 (en) 2019-06-13
MY205498A (en) 2024-10-23
PH12020550722A1 (en) 2021-02-15
AU2018378981A1 (en) 2020-07-16
KR102756155B1 (ko) 2025-01-20
DK3720428T3 (da) 2023-03-20
EP3720428B1 (en) 2023-01-11
MA50991A (fr) 2020-10-14
EP3720428A1 (en) 2020-10-14
BR112020011160A2 (pt) 2020-11-17
ZA202003944B (en) 2022-12-21
KR20200096569A (ko) 2020-08-12
HRP20230319T1 (hr) 2023-05-12
CN111542316A (zh) 2020-08-14
FI3720428T3 (fi) 2023-03-30
ES2941036T3 (es) 2023-05-16
SI3720428T1 (sl) 2023-05-31
US20200390729A1 (en) 2020-12-17
CA3083835A1 (en) 2019-06-13
PL3720428T3 (pl) 2023-05-08
MX2020005809A (es) 2020-08-20
JP2021505554A (ja) 2021-02-18
SG11202004940VA (en) 2020-06-29
MA50991B1 (fr) 2023-03-31
HUE061852T2 (hu) 2023-08-28
PT3720428T (pt) 2023-04-03
CL2020001426A1 (es) 2020-11-06

Similar Documents

Publication Publication Date Title
Gaballa et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives
CN1318093C (zh) 含与聚乙二醇结合的药物的眼组织注射剂
US20120101046A1 (en) Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
US20110117189A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
AU2018378981B2 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
US20150342874A1 (en) Ophthalmic Formulations of Squalamine
US10357453B2 (en) Methods of eye treatment using therapeutic compositions containing dipyridamole
EP2251009B1 (en) Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
JP2967523B2 (ja) 眼病用製薬組成物
HK40036612A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
HK40036612B (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
CA2442296C (en) Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients
WO2006098292A1 (ja) 眼疾患治療剤
AU2015258244C1 (en) Ophthalmic formulations of squalamine
KR20240019817A (ko) 퇴행성 망막 질환에 사용하기 위한 trpa1 채널 길항제 화합물
HK1228731A1 (en) Ophthalmic formulations of squalamine
HK1166605A (en) Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)